Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients
Javid Moslehi, MD provides expert insights into baseline and surveillance cardiac testing for individuals receiving immunotherapy.
EP: 1.An Overview of the Landscape Surrounding Melanoma
EP: 2.The Role of Biomarker Testing in Melanoma
EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma
EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting
EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy
EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma
EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy
EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes
EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective
EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management
EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis
EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy
EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients
EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities
EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment
This is a video synopsis/summary of an OncLive Insights involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.
Dr Shariff asks about checking baseline and serial troponins in asymptomatic immunotherapy patients. Dr Moslehi strongly recommends baseline EKG and troponin testing in all patients before starting immunotherapy to help determine whether symptoms later develop on treatment. However, routine troponin surveillance remains controversial, especially since baseline elevations occur in a substantial portion of patients, confounding interpretation of subsequent levels. Ultimately whether baseline troponins should change immunotherapy decision-making requires further study.
Dr Khushalani agrees routine surveillance troponins are not done presently but notes emerging data on increased myocarditis with certain immunotherapy combinations warrant caution during patient counseling. Dr Shariff concludes there is still much debate around optimal troponin testing approaches that impact management.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
